Lexeo Therapeutics, Inc. 8K

Lexeo Therapeutics reported Q2 2026 financial results and major pipeline updates, including initiation of its pivotal LX2006 trial and FDA RMAT designation for LX2020, supported by a cash runway projected into 2028.

On August 12, 2026, Lexeo Therapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026 and provided operational updates, highlighting the finalization and initiation of the pivotal SUNRISE-FA 2 trial and statistical analysis plan for LX2006 in Friedreich ataxia cardiomyopathy under an accelerated approval strategy, ongoing enrollment in the CLARITY-FA natural history study, recent publication and presentation of supportive LX2006 clinical and preclinical data, receipt of FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy along with favorable interim safety observations, preclinical proof-of-concept data for LX2022, and a cash, cash equivalents, and investments balance of $234.2 million that the company expects will fund operations into 2028 alongside a quarterly net loss of $25.9 million.

Filing Facts

CIK

1907108

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-345722

Alert Tier

6